Stand with Science. Support Health Equity. Help the World Discover a Promising New Alzheimer’s Treatment.
More than 55 million people live with Alzheimer’s — but global access to treatment is deeply unequal.
Despite limited resources, Cuba’s public biotech sector developed NeuroEPO, a treatment that has shown promising results in slowing the disease’s progression. But access, visibility, and support are blocked by U.S. sanctions and outdated Cold War policies.
Scientist Teresita Rodríguez and her team — made up largely of women — are leading a story of science, care, and resistance.
The film’s engagement campaign is about recognizing that story, sharing it, and building bridges that can shift how the world treats aging, illness, and its people.
Support health equity. Stand with Cuba’s scientists. Help shift the conversation on Alzheimer’s.
Teresita’s Dream isn’t just a film. It’s a call to reimagine global health — and to stand in solidarity with those pushing for solutions against the odds.
A discovery with the power to change how the world treats Alzheimer’s is in danger. With your support, this story can continue.
Be the first to watch Teresita’s Dream when it’s released. Sign up here to get notified as soon as the film goes live.
WAYS TO TAKE ACTION
Watch and share the film
Whether you’re an educator, caregiver, health advocate, or simply someone who believes in science and justice — start by watching the film. Then share it with someone who needs to see it.
Work against a policy that makes scientific collaboration challenging
Help challenge policies that make international scientific partnerships harder, especially between Cuba and the U.S. Stay informed, and amplify stories like Teresita’s that expose the cost of political barriers on human lives.
Bring the film to your community
Host a screening in your:
High school or college classroom
Community of faith
Retirement home
Medical school
Senior center
Local hospital
Book club
Public library
Local film series
We'll provide a discussion guide, outreach templates, and a screening toolkit to make it easy.